Safety of mRNA BNT162b2 COVID-19 (Pfizer-BioNtech) vaccine in children aged 5-11 years: Correspondence
Saved in:
Main Authors: | Rujittika Mungmunpuntipantip (Author), Viroj Wiwanitkit (Author) |
---|---|
Format: | Book |
Published: |
Taylor & Francis Group,
2022-12-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Safety of mRNA BNT162b2 COVID-19 (Pfizer-BioNtech) vaccine in children aged 5-11 years: Author's reply to correspondence
by: Giancarlo Ripabelli, et al.
Published: (2023) -
Analysis of intracranial haemorrhage following tozinameran (BNT162b2, Pfizer-BioNTech)
by: Yohhei Hamada
Published: (2021) -
A case of extensive alopecia areata following Pfizer‐BioNTech BNT162b2 mRNA COVID‐19 vaccine with favorable outcome
by: Yoshihiro Matsuda, et al.
Published: (2023) -
Neutrophilic urticarial dermatosis following BNT162b2 (Pfizer-BioNTech) COVID‐19 vaccination
by: Akihiro Matsubara, et al.
Published: (2021) -
Erythema multiforme reactions after Pfizer/BioNTech (BNT162b2) and Moderna (mRNA-1273) COVID-19 vaccination: A case series
by: Elif Karatas, MD, et al.
Published: (2023)